Author | Youcef M. Rustum, PhD


Clinical Implications of 5-FU Modulation

July 01, 1999

In recent years, due to the advent of sensitive instrumentation and methodologies, it has been possible to identify parameters that predict the quality of response of individual patients to treatments for specific selected diseases,

Rational Design of Irinotecan Administration Based on Preclinical Models

August 01, 1998

Most clinical drug regimens for irinotecan (CPT-11 [Camptosar]) have been empirically based on classic in vivo pharmacokinetic and pharmacodynamic considerations. We propose an alternative approach that attempts to